Nitric oxide ( ⅐ NO) plays a central role in vascular homeostasis via regulation of smooth muscle relaxation and platelet aggregation. Although mechanisms for ⅐ NO formation are well known, removal pathways are less well characterized, particularly in cells that respond to ⅐ NO through activation of soluble guanylate cyclase. Herein, we report that ⅐ NO is catalytically consumed by prostaglandin H synthase-1 (PGHS-1) through acting as a reducing peroxidase substrate. With purified ovine PGHS-1, ⅐ NO consumption requires peroxide (LOOH or H 2 O 2 ), with a K m (app) for 15(S)hydroperoxyeicosatetraenoic acid (HPETE) of 3.27 ؎ 0.35 M. During this, 2 mol ⅐ NO are consumed per mol HPETE, and loss of HPETE hydroperoxy group occurs with retention of the conjugated diene spectrum. Hydroperoxide-stimulated ⅐ NO consumption requires heme incorporation, is not inhibited by indomethacin, and is further stimulated by the reducing peroxidase substrate, phenol. PGHS-1-dependent ⅐ NO consumption also occurs during arachidonate, thrombin, or A23187 activation of platelets (1-2 M⅐min ؊1 for typical plasma platelet concentrations) and prevents ⅐ NO stimulation of platelet soluble guanylate cyclase. Platelet sensitivity to ⅐ NO as an inhibitor of aggregation is greater using a platelet-activating stimulus (U46619) that does not cause ⅐ NO consumption, indicating that this mechanism overcomes the anti-aggregatory effects of ⅐ NO. Catalytic consumption of ⅐ NO during eicosanoid synthesis thus represents both a novel proaggregatory function for PGHS-1 and a regulated mechanism for vascular ⅐ NO removal.In the vasculature, strict control of nitric oxide ( ⅐ NO) bioactivity is essential for both maintaining vascular tone and inhibiting platelet aggregation. Reaction with oxyhemoglobin (oxyHb) 1 is generally viewed to be the major fate of ⅐ NO generated in the vasculature. However, recent work has shown that erythrocyte sequestration of hemoglobin, combined with flow, decreases oxyHb reaction with ⅐ NO and thus renders it less effective at antagonizing ⅐ NO bioactivity in the vessel lumen (1, 2). Also, the biological half-life of ⅐ NO, when determined under oxyHb-free conditions (0.1-3 s), is far shorter than expected rates of ⅐ NO autooxidation (3, 4). Both of these observations indicate that cell-dependent catalytic scavenging reactions will play a role in regulating ⅐ NO signaling. Under pathological conditions of vascular dysfunction, accelerated ⅐ NO loss is often observed (5-7). In hypertensive states, a role for superoxide (O 2 . ) reacting with ⅐ NO to form peroxynitrite (ONOO Ϫ ) accounts for removal of a proportion of ⅐ NO. However, this is by no means the only mechanism for ⅐ NO removal because it is incompletely restored by O 2 . scavengers (7). Nitric oxide consumption by bacterial flavohemoglobins forms NO 3 Ϫ via reaction with the oxy form (8 -10) and is a proposed defense against "nitrosative stress." Recently, rabbit and human 15-lipoxygenases were also found to catalytically consume ⅐ NO, through reaction with an en...